A recent municipal ordinance in São José do Rio Preto mandates that hospitals and clinics must report any serious reactions experienced by patients using weight loss pens to the local Health Secretary. This initiative is part of broader public health efforts to monitor the safety and efficacy of such weight loss treatments. In addition to reactions from weight loss pens, the ordinance includes the requirement to report severe cases of mumps and chickenpox, indicating a focus on epidemic prevention as well.

The municipal health authorities emphasize that this new measure aims to closely track the risks associated with the use of weight loss pens and evaluate potential outbreaks of the listed diseases. The decision aligns with the National Health Surveillance Agency's regulations, which dictate that weight loss medications should be used strictly under medical supervision to mitigate the dangers associated with self-medication. The government underscores the importance of medical guidance in ensuring patient safety.

Furthermore, the ordinance highlights the prohibition of selling specific weight loss medications, including Synedica and TG type Tirzepatida, and Retatrutida in Brazil. The enforcement of this reporting requirement and the prohibition of these medications reflect the authorities' commitment to protecting public health and managing the risks posed by both weight loss treatments and communicable diseases.